Blood glycemia-modulating effects of melanian snail protein hydrolysates in mice with type II diabetes.
Blood glycemia-modulating effects of melanian snail protein hydrolysates in mice with type II diabetes.
复制标题
DOI：
10.3892/ijmm.2017.2967
复制
发表时间：
2017-06
影响因子：
5.4
通讯作者：
Kim MR
中科院分区：
文献类型：
--
作者：
Choi JS;Kim JW;Park JB;Pyo SE;Hong YK;Ku SK;Kim MR
长期以来，淡水动物蛋白一直被用作营养补充剂。在这项研究中，发现黑蜗牛蛋白水解物(MPH)对适应45%大卡高脂饮食(HFD)的II型糖尿病小鼠具有抗糖尿病和保护肝肾损伤的作用。以125、250、500 mg/kg连续灌胃给药12周，观察其降血糖、保肝、保肾作用。糖尿病对照组小鼠体重、血糖和胰岛素水平增加，血清高密度脂蛋白(HDL)水平下降。此外，脂肪性肝炎、肝细胞肥大和脂滴沉积相关的肾小管空泡化变性病变增加，胰岛明显扩张和增生，胰升糖素和胰岛素产生细胞增加，内分泌胰腺和肝脏脂质过氧化的胰岛素/高血糖素细胞比率增加，酶原含量降低。此外，还观察到内源性抗氧化防御系统的恶化，与葡萄糖利用相关的肝葡萄糖激酶(GK)活性降低，与糖异生相关的磷酸烯醇式丙酮酸羧激酶(PEPCK)和葡萄糖-6-磷酸酶(G6pase)活性增加。然而，所有这些糖尿病并发症都被口服MPH以剂量依赖的方式显著抑制。此外，还观察到明显的剂量依赖性抑制肝脏的脂质过氧化作用，肝脏内源性抗氧化防御系统的耗竭，以及肝脏葡萄糖调节酶活性的变化。这项研究的结果表明，MPH具有强大的抗糖尿病作用，同时还可以改善II型糖尿病小鼠的相关并发症。剂量为125 mg/kg的MPH对HFD诱导的糖尿病和相关并发症的总体影响与二甲双胍(250 mg/kg)相似或更强。
Freshwater animal proteins have long been used as nutrient supplements. In this study, melanian snail (Semisulcospira libertina) protein hydrolysates (MPh) were found to exert anti-diabetic and protective effects against liver and kidney damage in mice with type II diabetes adapted to a 45% kcal high-fat diet (HFD). The hypoglycemic, hepatoprotective and nephroprotective effects of MPh were analyzed after 12 weeks of the continuous oral administration of MPh at 125, 250 and 500 mg/kg. Diabetic control mice exhibited an increase in body weight, and blood glucose and insulin levels, with a decrease in serum high-density lipoprotein (HDL) levels. In addition, an increase in the regions of steatohepatitis, hepatocyte hypertrophy, and lipid droplet deposit-related renal tubular vacuolation degenerative lesions were detected, with noticeable expansion and hyperplasia of the pancreatic islets, and an increase in glucagon- and insulin-producing cells, insulin/glucagon cell ratios in the endocrine pancreas and hepatic lipid peroxidation, as well as decreased zymogen contents. Furthermore, a deterioration of the endogenous antioxidant defense system was observed, with reduced glucose utilization related hepatic glucokinase (GK) activity and an increase in hepatic gluconeogenesis-related phosphoenolpyruvate carboxykinase (PEPCK) and glucose-6-phosphatase (G6pase) activity. However, all of these diabetic complications were significantly inhibited by oral treatment with MPh in a dose-dependent manner. In addition, the marked dose-dependent inhibition of hepatic lipid peroxidation, the depletion of the liver endogenous antioxidant defense system, and changes in hepatic glucose-regulating enzyme activities were also observed. The results of this study suggest that MPh exerts potent anti-diabetic effects, along with the amelioration of related complications in mice with type II diabetes. The overall effects of MPh at a dose of 125 mg/kg on HFD-induced diabetes and related complications were similar or more potent than those of metformin (250 mg/kg).